Cancer Gene Therapy (Chemokines)

MIP-1(alpha) Gene Transfer Reduced Tumorigenicity and Induced Protective Immunity

Published in Gene Therapy Weekly, February 24th, 1997

Gene transfer of the chemokines human macrophage inflammatory protein 1(alpha) (hu-MIP-1(alpha)) or murine macrophage inflammatory protein 1(alpha) (mu-MIP-1(alpha)) into an adenocarcinoma cell line reduced its tumorigenicity and induced protective immunity against parental challenge in an immunocompetent murine model.

Certain chemokines have shown chemotactic activity against leukocytes at inflammatory or tumor sites. Delivery of chemokine genes to tumors may be a mechanism for cancer gene therapy by which host immune responses are stimulated against certain cancers.

Japanese researchers Emi Nakashima and colleagues examined the effect of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-02-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry